ETHNOPHARMACOLOGICAL RELEVANCE:Ligusticum chuanxiong is a traditional medicinal herb widely used for conditions related to blood circulation, inflammation, and neurological dysfunction. Its extracts and major bioactive compounds, including tetramethylpyrazine and ferulic acid, have shown neuroprotective potential in experimental spinal cord injury (SCI). However, the broader preclinical evidence remains incompletely characterized.
AIM OF THE STUDY:This study aimed to systematically evaluate the efficacy and potential mechanisms of Ligusticum chuanxiong-derived interventions in experimental SCI.
METHODS:PubMed, Web of Science, Embase, CNKI, Wanfang, and VIP were systematically searched for animal studies evaluating Ligusticum chuanxiong-derived interventions in SCI models. The primary outcomes were BBB locomotor scores and inclined plane test performance. Secondary outcomes included inflammatory, oxidative stress, apoptotic, glial, and neuronal markers. Risk of bias was assessed using the SYRCLE tool, and certainty of evidence using an adapted GRADE approach.
RESULTS:Forty animal studies were included. Ligusticum chuanxiong-derived interventions were associated with improved BBB scores at 3, 7, 14, 21, and 28 days after SCI, as well as improved inclined plane test performance from 7 to 21 days after injury. Mechanistic outcomes showed reduced IL-1β, MDA, and TUNEL-positive cells, together with increased SOD levels, suggesting potential neuroprotective effects through anti-inflammatory, antioxidant, and cell death-reducing mechanisms. At 28 days, immunofluorescence-based analyses indicated higher NeuN expression, whereas the pooled GFAP difference did not reach statistical significance; substantial heterogeneity limited certainty; caspase-3 expression was lower at 3 and 7 days, each based on three studies. Sensitivity analyses indicated that the BBB findings were generally robust, although potential publication bias or small-study effects were detected at several time points. An exploratory dose-time analysis of tetramethylpyrazine suggested that BBB effect sizes may increase over time, but the available evidence was insufficient to define an optimal dose.
CONCLUSION:Ligusticum chuanxiong-derived interventions may improve motor recovery after experimental SCI, potentially through modulation of inflammation, oxidative stress, and cell death. Further rigorously designed animal studies are needed to clarify active constituents, therapeutic windows, optimal dosing strategies, and translational potential.